Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anna N. Mendler"'
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Activation of co-stimulatory pathways in cytotoxic T lymphocytes expressing chimeric antigen receptors (CARs) have proven to boost effector activity, tumor rejection and long-term T cell persistence. When using antigen-specific T cell receptors (TCR)
Externí odkaz:
https://doaj.org/article/0de3501e8ca94ab1bedcd6a7f66b7639
Autor:
Angelika J. Fischbeck, Svenja Ruehland, Andreas Ettinger, Kerstin Paetzold, Ilias Masouris, Elfriede Noessner, Anna N. Mendler
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Adoptive T cell therapy (ACT) is highly effective in the treatment of hematologic malignancies, but shows limited success in solid tumors. Inactivation of T cells in the tumor milieu is a major hurdle to a wider application of ACT. Cytotoxicity is th
Externí odkaz:
https://doaj.org/article/302c86f4e7e749b2b3d6b3da0510006d
Autor:
Elfriede Noessner, Ralph Oberneder, Dorothee Brech, Anna N. Mendler, Petra U. Prinz, Ilias Masouris
Publikováno v:
International Journal of Cancer. 135:1832-1841
The relevance of NK cells in tumor control is well established in mouse models and human hematologic malignancies; however, their contribution to the control of human solid tumors remains disputed due to problems with in situ detection and reports of
Autor:
Laura Hinz, Niklas Muenchmeier, Nicole Rieth, Sophia Boecker, Peter J. Nelson, Elfriede Noessner, Anna N. Mendler, Lorenz Bankel, Constantin Lapa, Ralph Mocikat
Publikováno v:
PLoS ONE 8:e72749 (2013)
PLoS ONE, Vol 8, Iss 8, p e72749 (2013)
PLoS ONE
PLoS ONE, Vol 8, Iss 8, p e72749 (2013)
PLoS ONE
Background Cellular therapy is a promising therapeutic strategy for malignant diseases. The efficacy of this therapy can be limited by poor infiltration of the tumor by immune effector cells. In particular, NK cell infiltration is often reduced relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf2a98d899d7984ad7ae33146498458
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=27373
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=27373
Autor:
Rolf D. Issels, Jan C. Schmollinger, Marion Subklewe, Tina Adunka, Anna N. Mendler, Veit Bücklein, Elfriede Noessner
Publikováno v:
Oncoimmunology
OncoImmunology 5:e1178421 (2016)
OncoImmunology 5:e1178421 (2016)
Immunotherapy is currently investigated as treatment option in many types of cancer. So far, results from clinical trials have demonstrated that significant benefit from immunomodulatory therapies is restricted to patients with select histologies. To
Autor:
Ilias Masouris, Petra U. Prinz, Elfriede Noessner, Ralph Oberneder, Leopold Durner, Anna N. Mendler
Publikováno v:
J. Immunol. 188, 5990-6000 (2012)
CD8+ tumor-infiltrating T cells (CD8-TILs) are found in many types of tumors including human renal cell carcinoma. However, tumor rejection rarely occurs, suggesting limited functional activity in the tumor microenvironment. In this study, we documen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d04844889c4e3eb63670dfef6f239a6e
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=7569
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=7569
Publikováno v:
Int. J. Cancer 131, 633-640 (2012)
Lactic acidosis is common to most solid tumors and has been found to affect infiltrating immune cells. Here we document effector phase inhibition of cytotoxic T cells (CTLs) involving complete blockage of cytokine production and partial impairment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cefd153805d1019176259544d6f1180
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=6619
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=6619
Autor:
Niklas Muenchmeier, Sophia Boecker, Lorenz Bankel, Laura Hinz, Nicole Rieth, Constantin Lapa, Anna N Mendler, Elfriede Noessner, Ralph Mocikat, Peter J Nelson
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72749 (2013)
BACKGROUND: Cellular therapy is a promising therapeutic strategy for malignant diseases. The efficacy of this therapy can be limited by poor infiltration of the tumor by immune effector cells. In particular, NK cell infiltration is often reduced rela
Externí odkaz:
https://doaj.org/article/a767ad6f616b48279f2d0cdeb9ac8030